Abstract: The present invention relates to HLA-DR/CII peptide complexes comprising a chondroitinbinding peptide at the C-terminal end of the polypeptide comprising the H LA-DR alpha chain and/or the H LA-DR beta chain, wherein the CII peptide is fused to the N-terminus of the H LA-DR alpha chain or the H LA-DR beta chain by a linker peptide, for use in treating chronic inflammatory disease, such as arthritis, in human patients. The lysines in the CII peptide, particularly the first lysine in the CII peptide, may be post-translationally modified. The invention further relates to methods of producing said HLA-DR/CII peptide complexes in mammalian cells.